ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Respiratory · Lancet · 2026-07-17

In 558 infants with severe HIV-associated pneumonia in Africa, adding 15 days of valganciclovir to standard care did not significantly reduce day-15 deaths (23% vs 27%; rate ratio 0·81, p=0·15) or 12-month deaths (43% vs 48%); a time-varying model gave day-15 HR 0·60.

RCTn = 558
Moraleda et al. Empirical treatment with valganciclovir in infants living with HIV and hospitalised with severe pneumonia in Africa: a multicentre, open-label, factorial, randomised, controlled, superiority trial
Transplantation · Am J Transplant · 2026-05-21

In 70 high-CMV-risk kidney transplant recipients, maribavir 400 mg twice daily vs valganciclovir 900 mg daily prophylaxis showed no significant difference in clinically significant leukopenia (22.9% vs 5.7%, P=.084); valganciclovir had more days with low white cell counts.

RCTn = 70
Taber et al. Single-center, open-label, randomized controlled trial comparing the tolerability of maribavir 400 mg twice daily versus standard-dose valganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.